MAI Capital Management reported Adamas Pharmaceuticals Inc (ADMS) in 2 quarterly 13F filings .
This page tracks quarterly shares, estimated market value, portfolio weight, filing dates, and disclosure-aligned stock prices directly from SEC EDGAR 13F filings. Older history is available after unlock; the visible window still shows the most recent pattern.
This page is designed to answer the real investor question behind a 13F filing: how meaningful was MAI Capital Management's position in Adamas Pharmaceuticals Inc, and how did that conviction change over time? You can read the holding window, peak weight, latest reported size, disclosure timing, and quarter-by-quarter changes without piecing the story together from raw SEC rows.
See the most recent quarter where the fund disclosed this position.
Peak weight helps separate a token disclosure from a real conviction holding the fund genuinely cared about.
Longer holding windows often tell a very different story from short-lived tactical trades or one-quarter experiments.
Knowing that a fund owned a stock is useful. Knowing whether it was a 0.20% placeholder or a true high-conviction position is where the signal actually starts.
As of 2021 Q3 β sorted by position size
These are the practical questions this page is built to answer before you even open the full history table.
MAI Capital Management reported ADMS across 0 quarterly 13F filings.
This page shows the quarter-by-quarter portfolio weight history for ADMS in MAI Capital Management.
The most recent filing on this page is 2021 Q3, when MAI Capital Management reported 667,546 shares, equal to 0.06% of portfolio, with an estimated market value of $3.3M.
The chart compares MAI Capital Management's quarterly ADMS portfolio weight with the stock's indexed share price, so you can see whether the fund was building, trimming, or holding the position as price moved.